Tevogen Bio (TVGN) Expected to Announce Earnings on Friday

Tevogen Bio (NASDAQ:TVGN) is anticipated to post its results before the market opens on Friday, May 15th. Analysts expect Tevogen Bio to post earnings of ($2.00) per share for the quarter.

Tevogen Bio Stock Performance

TVGN opened at $6.97 on Wednesday. Tevogen Bio has a one year low of $4.14 and a one year high of $75.50. The stock’s fifty day moving average is $6.53 and its 200-day moving average is $14.88. The company has a market capitalization of $29.00 million, a PE ratio of -0.73 and a beta of 0.09.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wall Street Zen downgraded Tevogen Bio to a “strong sell” rating in a research note on Saturday, March 21st. D. Boral Capital downgraded Tevogen Bio from a “buy” rating to a “hold” rating in a research note on Wednesday, March 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Monday, April 20th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus price target of $100.00.

Hedge Funds Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently modified their holdings of TVGN. Bridgeway Capital Management LLC boosted its position in shares of Tevogen Bio by 66.7% in the 3rd quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Tevogen Bio by 126.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock valued at $91,000 after purchasing an additional 152,572 shares during the period. Finally, Deutsche Bank AG boosted its position in shares of Tevogen Bio by 304.1% in the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock valued at $57,000 after purchasing an additional 130,738 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.